PYY peptide YY 3-36
Selected indexed studies
- Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. (Physiol Rev, 2017) [PMID:28003328]
- Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation. (Bioengineered, 2022) [PMID:35443853]
- Peptide YY. (Curr Opin Endocrinol Diabetes Obes, 2008) [PMID:18185065]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. (2017) pubmed
- Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation. (2022) pubmed
- Peptide YY. (2008) pubmed
- Peptide-YY(3-36)/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries. (2022) pubmed
- Rational Development of Stable PYY(3-36) Peptide Y(2) Receptor Agonists. (2021) pubmed
- Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. (2006) pubmed
- Half-Life Extending Modifications of Peptide YY(3-36) Direct Receptor-Mediated Internalization. (2019) pubmed
- Peptide YY (3-36) modulates intracellular calcium through activation of the phosphatidylinositol pathway in hippocampal neurons. (2018) pubmed
- The postprandial secretion of peptide YY(1-36) and (3-36) in obesity is differentially increased after gastric bypass versus sleeve gastrectomy. (2023) pubmed
- Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY(3)(-)(36) in the suppression of food, drug-seeking, and anxiogenesis. (2024) pubmed